The demand for Human Immunoglobulin for Intravenously Injection is growing due to rising disease outbreaks around the globe. Moreover, increasing approval of new intravenous human immunoglobulin products by regulatory authorities are projected to drive the growth of the human immunoglobulin (ph4) for intravenous injection (COVID-19) market. For instance, in March 2019, CSL Behring, a manufacturer of plasma-derived and recombinant therapeutics, obtained approval from Japan’s Ministry of Health, Labour and Welfare Privigen, an intravenous immunoglobulin (IVIG), for treatment of patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/3790
Key players are accelerating their research and development activities in order to develop a treatment for the COVID-19 disease which is expected to boost the market growth during the forecast period. For instance, March 4, 2020, Takeda Pharmaceutical Company Limited informed the United States Congress that it is initiating the development of an anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG), TAK-888, to treat patients with COVID-19.
Furthermore, on April 6, 2020, Biotest Pharmaceuticals Corporation, BPL, LFB, and Octapharma AG joined the alliance formed by CSL Behring and Takeda Pharmaceutical Company Limited for the development of plasma-derived therapy to treat COVID-19.
Key Takeaways of the Global Human Immunoglobulin (ph4) for Intravenous injection (COVID-19) Market:
- The global human immunoglobulin (pH4) for intravenous injection (COVID-19) market is expected to exhibit a CAGR of 12.7% during the forecast period owing to the viral disease outbreak. According to the World Health Organization, around 464,212 cases of coronavirus disease were reported in Europe on April 1, 2020.
- Among Type, the IgG segment held a higher market share in 2019 owing to an increase in product approvals. For instance, on April 2019, ADMA Biologics, Inc. received approval from the U.S. Food and Drug Administration (FDA) for ASCENIV, human immune globulin intravenous (IgG) solution, for treatment of primary humoral immunodeficiency disease in adults and adolescents (12 to 17 years of age).
- Among disease indication, the primary immunodeficiency disease segment held a higher market share in 2019 owing to the growing prevalence of primary immunodeficiency diseases. For instance, United Kingdom Primary Immunodeficiency (UKPID) Registry estimated that around 4758 people were suffering from primary immunodeficiency disease in UK in 2017. However, due to coronavirus outbreak, demand for immunoglobulin products is expected to increase. As a result, the COVID-19 segment is expected to hold the highest market share in 2020.
- Companies operating in the global Human Immunoglobulin (pH4) for Intravenous injection (COVID-19) market are Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Behring, Bayer AG, Grifols, S.A., Octapharma AG, Shanghai RAAS Blood Products Co., Ltd., Hualan Biological Engineering Inc, China Biologic Products, Inc., Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd., Boya Bio-Pharmaceutical Group Co., Ltd., ADMA Biologics, Inc., and Sinopharm Group Co., Ltd.
Click Here to Get a Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/3790
The Study Objectives are:
✔ A comprehensive insight into key players operating in the Human Immunoglobulin (pH4) for Intravenous injection (COVID-19) Market and their corresponding data.
✔ It includes product portfolio, annual revenue, expenditure on research and development, geographical presence, key developments in recent years, and growth strategies.
✔ Regional analysis, which includes insight into the dominant market and corresponding market share.
✔ It also includes various socio-economic factors affecting the evolution of the market in the region.
✔ The report offers a comprehensive insight into different individuals from value chains such as raw materials suppliers, distributors, and stockholders.
Table of Content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Human Immunoglobulin (pH4) for Intravenous injection (COVID-19) Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Human Immunoglobulin (pH4) for Intravenous injection (COVID-19) Industry Impact
Chapter 2 Global Human Immunoglobulin (pH4) for Intravenous injection (COVID-19) Competition by Types, Applications, and Top Regions and Countries
2.1 Global Human Immunoglobulin (pH4) for Intravenous injection (COVID-19) (Volume and Value) by Type
2.3 Global Human Immunoglobulin (pH4) for Intravenous injection (COVID-19) (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Human Immunoglobulin (pH4) for Intravenous injection (COVID-19) Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 North America Human Immunoglobulin (pH4) for Intravenous injection (COVID-19) Market Analysis
Chapter 6 East Asia Human Immunoglobulin (pH4) for Intravenous injection (COVID-19) Market Analysis
Chapter 7 Europe Human Immunoglobulin (pH4) for Intravenous injection (COVID-19) Market Analysis
Chapter 8 South Asia Human Immunoglobulin (pH4) for Intravenous injection (COVID-19) Market Analysis
Chapter 9 Southeast Asia Human Immunoglobulin (pH4) for Intravenous injection (COVID-19) Market Analysis
Chapter 10 Middle East Human Immunoglobulin (pH4) for Intravenous injection (COVID-19) Market Analysis
Chapter 11 Africa Human Immunoglobulin (pH4) for Intravenous injection (COVID-19) Market Analysis
Chapter 12 Oceania Human Immunoglobulin (pH4) for Intravenous injection (COVID-19) Market Analysis
Chapter 13 South America Human Immunoglobulin (pH4) for Intravenous injection (COVID-19) Market Analysis
Chapter 14 Company Profiles and Key Figures in Human Immunoglobulin (pH4) for Intravenous injection (COVID-19) Business
Chapter 15 Global Human Immunoglobulin (pH4) for Intravenous injection (COVID-19) Market Forecast (2022-2028)
Chapter 16 Conclusions
Research Methodology
Customization of the Report
Our research analysts will help you to get customized details for your report, which can be modified in terms of a specific region, application or any statistical details. In addition, we are always willing to comply with the study, which triangulated with your own data to make the market research more comprehensive in your perspective.
Buy This Complete Business Report @ https://www.coherentmarketinsights.com/insight/buy-now/3790
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837